How to manage patients with nccRCC 

In this clinical topic video, medical oncologist Prof. Laurence Albiges shares her perspective on the challenges related to treating nccRCC, the emergence of combination treatments, guideline recommendations, and the importance of shared decision-making with patients. 

 

Prof. Albiges reviews data from key trials linked to recommendations from the NCCN and ESMO guidelines and discusses the heterogeneous nature of nccRCC and the diverse histological subtypes, along with the importance of correct diagnosis to ensure treatment regimens are individualised based on the relevant histological subtype. 

 

Watch the video and download the accompanying slide set for more details.

 

Clinical takeaways

  • Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease that encompasses a diverse subset of histological subtypes
  • Large prospective studies relevant to a single histology of nccRCC have been limited, and treatment options have been scarce
  • Treatment regimens should be individualised based on the histological subtype
    (e.g. papillary, chromophobe, or collecting duct carcinoma), molecular characteristics, and the presence of metastases but more data is needed to determine optimal treatment according to these features
  • In the absence of clinical trial availability, tyrosine kinase inhibitors (TKIs) and immune checkpoint blockade combinations may be prescribed for metastatic disease; multiple trials of these agents are ongoing

  • Understand and be able to differentiate the efficacy and safety profiles of targeted and immunotherapies for nccRCC
  • Be able to discuss the risks and benefits of therapy with patients and understand the importance of shared decision-making

Professor Laurence Albiges is a medical oncologist and head of the Department of Oncology at Gustave Roussy.

Her main areas of interest are new therapies for metastatic kidney cancer and rare forms of renal cell carcinoma. She is currently developing translational research programs on these topics. Laurence Albiges is the author of numerous publications in recognized scientific journals. She is associate editor of the journal European Urology Oncology.

As a result of her research work, she has received several distinctions, awards and funding, including the Conquer Cancer Foundation Merit Award at the ASCO Genitourinary Symposium in 2015 and the Unicancer-Fondation de France grant. Her research on biomarkers of response to immunotherapy is funded by a K-RTP award.

Prof. Laurence Albiges is a member of the GETUG steering committee and of the EAU (European Association of Urology) guidelines panel for kidney cancer. She is involved in the ESMO (European Society for Medical Oncology) where she has been a member of the scientific committee of the congress since 2017. She belongs to the cancer committee of the French association of urology. She belongs to the scientific board of the EIKCS (European International Kidney Cancer Symposium) and EMUC (European Multidisciplinary Congress on Urological Cancers). She is a member of the scientific board of the KCA (Kidney Cancer Association).

Prof. Laurence Albiges has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.